These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25359988)

  • 1. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
    Hoelzer D; Walewski J; Döhner H; Viardot A; Hiddemann W; Spiekermann K; Serve H; Dührsen U; Hüttmann A; Thiel E; Dengler J; Kneba M; Schaich M; Schmidt-Wolf IG; Beck J; Hertenstein B; Reichle A; Domanska-Czyz K; Fietkau R; Horst HA; Rieder H; Schwartz S; Burmeister T; Gökbuget N;
    Blood; 2014 Dec; 124(26):3870-9. PubMed ID: 25359988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
    Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
    Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
    Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
    Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
    Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
    Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
    Wästerlid T; Brown PN; Hagberg O; Hagberg H; Pedersen LM; D'Amore F; Jerkeman M
    Ann Oncol; 2013 Jul; 24(7):1879-1886. PubMed ID: 23446093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.
    Intermesoli T; Rambaldi A; Rossi G; Delaini F; Romani C; Pogliani EM; Pagani C; Angelucci E; Terruzzi E; Levis A; Cassibba V; Mattei D; Gianfaldoni G; Scattolin AM; Di Bona E; Oldani E; Parolini M; Gökbuget N; Bassan R
    Haematologica; 2013 Nov; 98(11):1718-25. PubMed ID: 23753030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.
    Kasamon YL; Brodsky RA; Borowitz MJ; Ambinder RF; Crilley PA; Cho SY; Tsai HL; Smith BD; Gladstone DE; Carraway HE; Huff CA; Matsui WH; Bolaños-Meade J; Jones RJ; Swinnen LJ
    Leuk Lymphoma; 2013 Mar; 54(3):483-90. PubMed ID: 22835045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
    Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved outcome in adult B-cell acute lymphoblastic leukemia.
    Hoelzer D; Ludwig WD; Thiel E; Gassmann W; Löffler H; Fonatsch C; Rieder H; Heil G; Heinze B; Arnold R; Hossfeld D; Büchner T; Koch P; Freund M; Hiddemann W; Maschmeyer G; Heyll A; Aul C; Faak T; Kuse R; Ittel TH; Gramatzki M; Diedrich H; Kolbe K; Fuhr HG; Fischer K; Schadeck-Gressel C; Weiss A; Strohscheer I; Metzner B; Fabry U; Gökbuget N; Völkers B; Messerer D; Uberla K
    Blood; 1996 Jan; 87(2):495-508. PubMed ID: 8555471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial.
    Vellenga E; van Putten WL; van 't Veer MB; Zijlstra JM; Fibbe WE; van Oers MH; Verdonck LF; Wijermans PW; van Imhoff GW; Lugtenburg PJ; Huijgens PC
    Blood; 2008 Jan; 111(2):537-43. PubMed ID: 17971487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
    [No Abstract]   [Full Text] [Related]  

  • 18. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
    Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
    Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation.
    Broccoli A; Argnani L; Gugliotta G; Pellegrini C; Casadei B; Bagnato G; Gentilini M; Stefoni V; Zinzani PL
    Oncologist; 2024 Jun; 29(6):e789-e795. PubMed ID: 38339976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.